^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GEN-001

i
Other names: GEN-001, LR20011, GEN 001, GEN001, LR-20011, LR 20011
Associations
Company:
Genome & Company, LG Chem
Drug class:
T-cell stimulant, Dendritic cell activator, IL-15 stimulant, IL-7 agonist
Related drugs:
Associations
11ms
Phase II study of GEN-001 in combination with avelumab in patients with PD-L1–positive locally advanced, or metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) who have progressed after second-line (2L) and beyond (GEN001-201 study). (ASCO-GI 2024)
Treatment of patients with GC/GEJC with GEN-001 in combination with avelumab in the ≥ 3L setting showed promising antitumor activities with an overall manageable safety profile. The results from this trial will be updated about its effects on clinical outcome, including survival, safety, and biomarker findings. Clinical trial information: NCT05419362.
Clinical • P2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Bavencio (avelumab) • GEN-001
1year
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (clinicaltrials.gov)
P2, N=42, Active, not recruiting, Genome & Company | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Bavencio (avelumab) • GEN-001
1year
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer (clinicaltrials.gov)
P2, N=148, Recruiting, Genome & Company | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • GEN-001
over1year
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (clinicaltrials.gov)
P2, N=42, Recruiting, Genome & Company | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Bavencio (avelumab) • GEN-001
over2years
New P2 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Bavencio (avelumab) • GEN-001
3years
Clinical • New trial
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
GEN-001